← Back to Clinical Trials
Recruiting NCT06941753

NCT06941753 Off-script Diagnosis & Differential Diagnosis (D&D) Training and Residents' Stroke Knowledge

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06941753
Status Recruiting
Phase
Sponsor Peking Union Medical College Hospital
Condition Stroke, Acute
Study Type INTERVENTIONAL
Enrollment 22 participants
Start Date 2025-06-20
Primary Completion 2027-07-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Off-script diagnosis & differential diagnosis (D&D) training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 22 participants in total. It began in 2025-06-20 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is a single-center, randomized, open-label, controlled, endpoint-blinded study to assess the effect of off-script diagnosis \& differential diagnosis (D\&D) training in improving the residents' knowledge of acute ischemic stroke in China. The investigators will enroll 22 residents and assess the score of mASMaQ 30 days after randomization.

Eligibility Criteria

Inclusion Criteria: 1. Residents (physicians in postgraduate training). 2. Currently in neurology wards 3. Managing acute ischemic stroke (AIS) patients, defined as: 1)Time from onset to randomization ≤ 2 weeks; 2) If onset time is unknown, the last known well time is considered the onset time. 4. Signed informed consent Exclusion Criteria: 1. Managing asymptomatic ischemic stroke patients. 2. Residents who are currently participating or have participated in another interventional ischemic stroke training program within the past 3 months.

Contact & Investigator

Central Contact

Shengde Li, MD

✉ lishengde.medicine@qq.com

📞 17896002828

Principal Investigator

Jun Ni, MD

PRINCIPAL INVESTIGATOR

Peking Union Medical College Hospital

Frequently Asked Questions

Who can join the NCT06941753 clinical trial?

This trial is open to participants of all sexes, studying Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06941753 currently recruiting?

Yes, NCT06941753 is actively recruiting participants. Contact the research team at lishengde.medicine@qq.com for enrollment information.

Where is the NCT06941753 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06941753 clinical trial?

NCT06941753 is sponsored by Peking Union Medical College Hospital. The principal investigator is Jun Ni, MD at Peking Union Medical College Hospital. The trial plans to enroll 22 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology